Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-10
2009-12-01
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S471000, C536S023100, C536S024320, C536S024500
Reexamination Certificate
active
07625873
ABSTRACT:
A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tmof between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.
REFERENCES:
patent: 5185444 (1993-02-01), Summerton
patent: 5749847 (1998-05-01), Zewert et al.
patent: 5892023 (1999-04-01), Pirotzky et al.
patent: 6030954 (2000-02-01), Wu et al.
patent: 6060456 (2000-05-01), Arnold et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6228579 (2001-05-01), Zyskind et al.
patent: 6239265 (2001-05-01), Cook
patent: 6495663 (2002-12-01), Rothbard et al.
patent: 6677153 (2004-01-01), Iversen
patent: 6784291 (2004-08-01), Iversen et al.
patent: 6828105 (2004-12-01), Stein et al.
patent: 6841542 (2005-01-01), Bartelmez
patent: 7049431 (2006-05-01), Iversen et al.
patent: 7094765 (2006-08-01), Iversen et al.
patent: 2003/0095953 (2003-05-01), Cabot et al.
patent: 2003/0166588 (2003-09-01), Iversen et al.
patent: 2003/0175767 (2003-09-01), Davis et al.
patent: 2003/0224353 (2003-12-01), Stein et al.
patent: 2006/0281701 (2006-12-01), Stein et al.
patent: 2007/0021362 (2007-01-01), Geller et al.
patent: 2007/0135333 (2007-06-01), Geller et al.
patent: 2008/0194463 (2008-08-01), Weller et al.
patent: WO 01/49775 (2001-07-01), None
patent: WO 02/079467 (2002-10-01), None
patent: WO 02/079467 (2002-10-01), None
patent: WO 02/094250 (2002-11-01), None
patent: WO 2006/047683 (2006-05-01), None
International Search Report for PCT/US05/023553, AVI Biopharma, Inc., Nov. 8, 2006.
Deere et al.,Antimicrobial Agents and Chemotherapy, 49(1):249-255 (2005).
Dryselius et al.,Oligonucleotides, 13(6):427-33 (2003).
Geller et al.,Antimicrob Agents Chemother., 47(10):3233-9 (2003).
Good et al.,Nature Biotechnology, 19(4):360-364 (2001).
Nielsen, P. E.,Expert Opinion on Investigational Drugs, 10(2):331-341 (2001).
Wang et al.,FEMS Microbiology Letters, 220(2):171-176 (2003).
Agrawal, Sudhir,Tibtech, 14:376-387 (1996).
Agrawal et al.,Molecular Med. Today, 6:72-81 (2000).
Bailey, C. P., J. M. Dagle et al., “Cationic oligonucleotides can mediate specific inhibition of gene expression in Xenopus oocytes.”Nucleic Acids Res, 26(21): 4860-7 (1998).
Barawkar, D. A. and T. C. Bruice, “Synthesis, biophysical properties, and nuclease resistance properties of mixed backbone oligodeoxynucleotides containing cationic internucleoside guanidinium linkages: deoxynucleic guanidine/DNA chimeras.”Proc Natl Acad Sci U S A, 95(19): 11047-52. (1998).
Branch et al.,Trends in Biochem. Sci., 23:45-50 (1998).
Chirilla et al.,Biomaterials, 23:321-342 (2002).
Crooke, S.T.,Antisense Res. And Applica., 1-50. S. Crooke, ed. Springer. (1999).
Gilbert et al.,J. Clinical Epidemiology, 54:68-85 (2001).
Green et al.,J. Am. Coll. Surg., Collective Review 93-105.
Hudziak et al.,Antisnese&Nucleic Acid Drug Dev., 6:267-272 (1996).
Jen et al.,Stem Cells, 18:307-319.
Linkletter, B. A. and Bruice, T.C., “Solid-phase synthesis of positively charged deoxynucleic guanidine (DNG) modified oligonucleotides containing neutral urea linkages: Effect of charge deletions on binding and fidelity.”Bioorg. Med. Chem. 8(11): 1893-1901 (2000).
Micklefield, J., “Backbone modification of nucleic acids: synthesis, structure and therapeutic applications.”Curr Med Chem, 8(10):1157-79 (2001).
Nelson, M. H., D. A. Stein, et al. (2005). “Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.”Bioconjug Chem16(4): 959-66.
Palu et al.,J. Biotech., 68:1-13 (1999).
Summerton et al.,Antisense&Nucleic Acid Drug Development, 7:63-70 (1997).
Summerton et al.,Biochim et. Biophys. ACTA, 1489:141-158 (1999).
Summerton, J. and D. Weller (1997). “Morpholino antisense oligomers: design, preparation, and properties.”Antisense Nucleic Acid Drug Dev7(3) : 187-95.
Zollinger et al.,Transactions of Royal Soc of Tropical Medicine and Hygiene., 85(Supp. 1) pp. 37-43 (1991).
Blommers, M. J., U. Pieles, et al., “An approach to the structure determination of nucleic acid analogues hybridized to RNA. NMR studies of a duplex between 2′-OMe RNA and an oligonucleotide containing a single amide backbone modification.”Nucleic Acids Res., 22(20):4187-94 (1994).
Bramhill, D., “Bacterial cell division”,Annu Rev Cell Dev Biol., 13:395-424 (1997).
Cross et al., “Solution structure of an RNA x DNA hybrid duplex containing a 3′-thioformacetal linker and an RNA A-tract”,Biochemistry, 36(14):4096-107 (1997).
Dagle et al., “Targeted elimination of zygotic messages in Xenopus laevis embryos by modified oligonucleotides possessing terminal cationic linkages”,Nucleic Acids Research, 28(10):2153-2157 (2000).
Donachie, W. D., “The cell cycle ofEscherichia coli”, Annu Rev Microbiol., 47:199-230 (1993).
Gait et al., “Synthetic-analogues of polynucleotides XII. Synthesis of thymidine derivatives containing an oxyacetamido- or an oxyformamido-linkage instead of a phosphodiester group”,J Chem Soc [Perkin 1]0(14):1684-6 (1974).
Galloway, S. M. and Raetz, C.R., “A mutant ofEscherichia colidefective in the first step of endotoxin biosynthesis”,J. Biol Chem., 265(11):6394-402 (1990).
Geller, B. L. and Green, H.M., Translocation of pro-OmpA across inner membrane vesicles ofEscherichia colioccurs in two consecutive energetically distinct steps',J Biol Chem., 264(28):16465-9 (1989).
Gerdes et al., “Experimental determination and system level analysis of essential genes inEscherichia coliMG1655”,J Bacteriol., 185(19):5673-84 (2003).
Good et al., “Antisense PNA effects inEscherichia coliare limited by the outer-membrane LPS layer”,Microbiology, 146( Pt 10):2665-70 (2000).
Hale, C. A. and de Boer, P.A., “Recruitment of ZipA to the septal ring ofEscherichia coliis dependent on FtsZ and independent of FtsA”,J Bacteriol., 181(1):167-76.
Jackowski S. and Rock, C.O., “Ratio of active to inactive forms of acyl carrier protein inEscherichia coli”,J Biol Chem., 258(24):15186-91 (1983).
Jackson et al., “Escherichia coliO157:H7 diarrhoea associated with well water and infected cattle on an Ontario farm”,Epidemiol. Infect., 120(1):17-20 (1998).
Knudsen, H. and Nielsen, P.E., “Antisense properties of duplex- and triplex-forming PNAs”,Nucleic Acids Res., 24(3):494-500 (1996).
Lesnikowski et al. “Octa(thymidine methanephosphonates) of partially defined stereochemistry: synthesis and effect of chirality at phosphorus on binding to pentadecadeoxyriboadenylic acid”,Nucleic Acids Res., 18(8):2109-15 (1990).
Lutkenhaus, J. and Addinall, S.G., “Bacterial cell division and the Z ring”,Annu Rev Biochem., 66:93-116 (1997).
Mertes, M. P. and Coats, E.A., “Synthesis of carbonate analogs of dinucleosides. 3′-Thymidinyl 5′-thymidinyl carbonate, 3′-thymidinyl 5′-(5-fluoro-2′-deoxyuridinyl) carbonate, and 3′-(5-fluoro-2′-deoxyuridinyl) 5′-thymidinyl carbonate”,J Med Chem., 12(1):154-7 (1969).
Miyada, C.G. and Wallace, R.B., “Oligonucleotide hybridization techniques”,Methods Enzymol., 154:94-107 (1987).
Moulton, H. M. and J. D. Moulton, “Peptide-assisted delivery of steric-blocking antisense oligomers.”Curr Opin Mol Ther., 5(2):123-32 (2003).
Moulton et al., “HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers”,Antisense Nucleic Acid
Deere Jesse D.
Geller Bruce L.
Iversen Patrick L.
Weller Dwight D.
AVI BioPharma Inc.
Seed IP Law Group PLLC
Zara Jane
LandOfFree
Antisense antibacterial method and compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense antibacterial method and compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense antibacterial method and compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4131033